|
Daily Medical Update
Osteoporosis (FRAX, Bisphosphonates, screening)
Saturday, February 14, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
1. FRAX-guided treatment thresholds better identify patients at near-term fracture risk
Osteoporos Int (2025) - Prospective Cohort/Guideline-Linked Analysis
Key Findings
- Adults above guideline FRAX thresholds had substantially higher major osteoporotic fracture incidence versus below-threshold groups during follow-up.
- Using FRAX + BMD in primary care improved treatment targeting and reduced low-value prescribing in lower-risk patients.
📋 Practice Implication: Standardize FRAX-based thresholding at osteoporosis visits to improve who gets treated and who can be observed.
|
2. Bisphosphonates remain first-line with strongest absolute benefit in highest-risk patients
J Clin Endocrinol Metab (2025) - Systematic Review/Meta-Analysis
Key Findings
- Pooled RCT evidence showed lower vertebral fracture risk with bisphosphonates versus placebo/usual care, with consistent benefit direction across agents.
- Absolute fracture-risk reduction was greatest in patients with prior fragility fracture or lower baseline BMD, supporting risk-prioritized initiation.
📋 Practice Implication: Prioritize early bisphosphonate initiation for clearly high-risk patients rather than delaying therapy for low-yield alternatives.
|
3. Stopping denosumab without transition therapy increases rebound vertebral fracture risk
Bone (2025) - Systematic Review
Key Findings
- Denosumab cessation without follow-on antiresorptive therapy was associated with increased vertebral fracture events compared with planned transition strategies.
- Transitioning to a bisphosphonate after denosumab reduced rebound bone loss and lowered subsequent fracture risk.
📋 Practice Implication: Treat denosumab discontinuation as a high-risk transition point and pre-plan a follow-on antiresorptive before stopping.
|
4. Post-fracture care pathways reduce recurrent fractures
JAMA Netw Open (2025) - Pragmatic Cluster Trial
Key Findings
- Fracture liaison-style pathways increased osteoporosis treatment initiation rates compared with usual post-discharge care.
- Sites using structured PCP follow-up reduced recurrent fragility fractures over follow-up versus usual-care pathways.
📋 Practice Implication: Implement a standard secondary-fracture workflow after any low-trauma fracture to close treatment gaps.
|
5. Drug-holiday timing should be risk-stratified, not automatic
JBMR Plus (2025) - Observational Comparative Effectiveness
Key Findings
- High-risk patients taking early bisphosphonate holidays had higher fracture rates versus those who continued therapy.
- Risk-guided continuation decisions based on age, prior fracture, and T-score produced better fracture outcomes than fixed-duration stopping rules.
📋 Practice Implication: Reassess risk before any bisphosphonate holiday and continue therapy in persistently high-risk patients.
|
|
Recent high-value osteoporosis evidence supports tighter risk-stratified care in primary care: use FRAX plus BMD to target treatment, keep bisphosphonates first-line for most high-risk adults, and avoid unplanned denosumab discontinuation. Practice-changing signals center on treatment-threshold precision, transition planning, and secondary-fracture prevention pathways.
|
|